Fred,
Regular insulin patents expired. Read the following from Biodel.
"-- Biodel entered into a supply agreement with Organon on July 7, 2008 to purchase specified quantities of recombinant human insulin for use in the company's VIAdel(TM) insulin formulations. The company believes that its current supplies of insulin, together with the quantities of insulin that Organon has agreed to supply, will be sufficient to complete the company's current and anticipated clinical trials of VIAject(TM) and support the company's needs for approximately three years following the commercial launch of VIAject(TM)."
Humulin R and Novolin R are trademarks for Regular Insulin.
Dr. Lim stated the 505 b 2 pathway and if a partner was not found, they would develope co-formulation for Regular Insulin inhouse. Anyone with serious questions such as how they can get Regular Insulin should contact company since that has not been made public and does not seem to be a legitimate point of concern but a good way to spread FUD.
Regular insulin patents expired. Read the following from Biodel.
"-- Biodel entered into a supply agreement with Organon on July 7, 2008 to purchase specified quantities of recombinant human insulin for use in the company's VIAdel(TM) insulin formulations. The company believes that its current supplies of insulin, together with the quantities of insulin that Organon has agreed to supply, will be sufficient to complete the company's current and anticipated clinical trials of VIAject(TM) and support the company's needs for approximately three years following the commercial launch of VIAject(TM)."
Humulin R and Novolin R are trademarks for Regular Insulin.
Dr. Lim stated the 505 b 2 pathway and if a partner was not found, they would develope co-formulation for Regular Insulin inhouse. Anyone with serious questions such as how they can get Regular Insulin should contact company since that has not been made public and does not seem to be a legitimate point of concern but a good way to spread FUD.
Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.
Recent HALO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:06:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 09:13:42 PM
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:29:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:28:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 10:35:07 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/23/2026 08:16:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/23/2026 08:13:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/23/2026 08:11:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:32:00 PM
- Halozyme Appoints David Ramsay as Interim Chief Financial Officer • PR Newswire (US) • 03/12/2026 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/10/2026 08:05:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:18:04 PM
- U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma • PR Newswire (US) • 03/06/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:56:16 PM
- Halozyme to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/25/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:16:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:12:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:53:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:52:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 11:51:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 09:04:55 PM
- HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE • PR Newswire (US) • 02/17/2026 09:01:00 PM
